French Multicentre Observational Study of a Prospective Cohort of Renal Transplant Patients Converted From the Twice Per Day Form of Tacrolimus (Prograf) to the Once Per Day Form (Advagraf)
Phase of Trial: Phase IV
Latest Information Update: 29 Sep 2017
Price : $35 *
At a glance
- Drugs Tacrolimus (Primary)
- Indications Renal transplant rejection
- Focus Pharmacokinetics; Therapeutic Use
- Acronyms OPALE
- Sponsors Astellas Pharma
- 31 Aug 2017 Status changed from active, no longer recruiting to completed.
- 12 May 2017 Planned End Date changed from 1 Mar 2017 to 15 May 2017.
- 12 May 2017 Planned primary completion date changed from 1 Mar 2017 to 15 May 2017.